|
|
Abstract
These days we all suffer from information overload. To overcome this problem,
the Gastrointestinal Drug News service focuses specifically on GI
drugs, delivering the information you need in a timely, flexible and
convenient format.
Long gone are the days when the GI market was dominated by H2 antagonists and
PPIs with the focus very much on conditions of the upper GI tract. The
treatment of GORD continues to be a growth market, but now growing clinical
awareness and improving rates of diagnosis are seeing conditions such as IBD
(ulcerative colitis, Crohn' s disease) and IBS take centre stage in future
plans - indeed, many feel that the potential patient population for these
conditions is only now beginning to be recognised.
For pharmaceutical company executives, researchers and commercial managers,
this sector is taking an important role in the industry' s plans; staying in
touch with the latest twists and turns, however, is another matter. That is
why this new, daily-updated online information service is essential.
The Gastrointesinal Drugs News information service provides:
- The full text of the latest news reported on all types of GI drugs and
their development
- An easy-to-use interface that immediately takes you to the most recently
updated information
- An extensive archive of over 2,120 articles which makes the service a
valuable tracking and research tool
- A fast and effective search facility allowing you to identify information
relevant to you
- Daily or weekly email alerts which will ensure you know when new
information is added
- An RSS feed facility
Every day, Espicom' s researchers and editors
- Track the companies and research organisations that are shaping the
industry
- Report the latest developments in current and up coming GI drugs
- Monitor results from major conferences and meetings
Gastrointestinal Drug News published by Espicom Business Intelligence. This newsletter price starts from US $ 690.
|
